Form 4: Protara Therapeutics Director Acquires Stock Options

Director Cynthia Smith acquired 10,000 stock options in Protara Therapeutics on June 7, 2024.

Summary

• Cynthia Smith, a director of Protara Therapeutics, acquired 10,000 stock options on June 7, 2024.
• The exercise price of the options is $2.67.
• The options vest in equal monthly installments over 12 months, fully vesting by the next annual stockholder meeting or upon a change of control, contingent on continuous service on the Board.
• The options expire on June 6, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction. A director acquiring stock options is generally a positive sign, but it's not a major event.

Positives

• A director's acquisition of stock options can be seen as a positive signal, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule of the options is tied to continued service on the board and a potential change of control, suggesting a long-term commitment from the director.

Industry Context

This is a standard Form 4 filing, reflecting a director's acquisition of stock options, a common form of executive compensation in publicly traded companies.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.

Key Dates